


IAS STATIN
NEWSLETTER



INTERNATIONAL
ATHEROSCLEROSIS
SOCIETY

A CURATED WEEKLY UPDATE OF ALL STATIN PUBLICATIONS

Update - February, 2022



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications February 2022

Add on treatments

1. Brailovski E, Li Q, Liu N *et al.* The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of hematology 2022.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=35190844>
2. Boudreau H, Blakeslee-Carter J, Novak Z *et al.* Association of Statin and Antiplatelet Use with Survival in Patients with AAA with and without Concomitant Atherosclerotic Occlusive Disease. Annals of vascular surgery 2022.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=35108555>
3. Xiong Z, Yi P, Tang X *et al.* Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. BioMed research international 2022; 2022:6747469.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=35178452>
4. Crupi R, Cuzzocrea S. Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance. Biomolecules 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35204743>
5. Groenendaal-van de Meent D, den Adel M, Kerbusch V *et al.* Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.

Clinical pharmacology in drug development 2022.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=35182045>

6. Yerino GA, Feleder EC, Halabe EK *et al.* Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide and rosuvastatin in healthy adult subjects. International journal of clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35103587>
7. Nelson AJ, O'Brien EC, Kaltenbach LA *et al.* Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA network open 2022; 5:e2148030. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175345>
8. Weintraub WS, Bhatt DL, Zhang Z *et al.* Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA network open 2022; 5:e2148172. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35157055>
9. Alshaya HA, Alfahad AJ, Alsulaimem FM *et al.* Fast-Dissolving Nifedipine and Atorvastatin Calcium Electrospun Nanofibers as a Potential Buccal Delivery System. Pharmaceutics 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35214093>
10. Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175631>

Adherence

1. Browning JA, Tsang CCS, Dong X *et al.* Effects of Medicare comprehensive medication review on racial/ethnic disparities in nonadherence to statin medications among patients with Alzheimer's Disease: an observational analysis. BMC Health Serv Res 2022; 22:159. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130899>
2. Zhang L, Wang W, Man F *et al.* The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome. Cardiovasc Drugs Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35138504>
3. Norberg H, Sjölander M, Glader EL, Gustafsson M. Self-reported medication adherence and pharmacy refill adherence among persons with ischemic stroke: a cross-sectional study. Eur J Clin Pharmacol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35156130>
4. Sverre E, Peersen K, Kristiansen O *et al.* Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects. Journal of internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35103360>
5. Santos AN, Rauschenbach L, Saban D *et al.* Medication intake and hemorrhage risk in patients with familial cerebral cavernous malformations. Journal of neurosurgery 2022:1-7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35213840>
6. Jeong W, Joo JH, Kim H *et al.* Association between statin adherence and the risk of stroke among South Korean adults with hyperlipidemia. Nutrition, metabolism, and cardiovascular diseases : NMCD 2022; 32:560-566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35105503>

Atherosclerosis – Plaque-Imaging

1. Verma KP, Marwick T, Duarte C *et al.* Use of Coronary Computed Tomography or Polygenic Risk Scores to Prompt Action to Reduce Coronary Artery Disease Risk:

- The CAPAR-CAD Trial. Am Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218726>
2. Dykun I, Bayturan O, Carlo J *et al.* HbA1c, Coronary atheroma progression and cardiovascular outcomes. Am J Prev Cardiol 2022; 9:100317. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112095>
 3. Boudreau H, Blakeslee-Carter J, Novak Z *et al.* Association of Statin and Antiplatelet Use with Survival in Patients with AAA with and without Concomitant Atherosclerotic Occlusive Disease. Annals of vascular surgery 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108555>
 4. Siudut J, Natorska J, Wypasek E *et al.* Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis. Atherosclerosis 2022; 344:49-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35134656>
 5. Zuo HJ, Nan N, Yang HX *et al.* Impact of Conventional Cardiovascular Risk Factors on Left Internal Mammary Artery Graft Disease. Frontiers in cardiovascular medicine 2021; 8:705765. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096986>
 6. Tsimikas S. Lipoprotein(a) and Coronary Calcium: Clinical Management and Potential Design of Primary Prevention Trials. J Am Coll Cardiol 2022; 79:769-771. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210031>
 7. Lu E, Hanson C, Beller G, Bourque J. Long-Term Outcomes are Similar Despite Sex Disparities in High-Intensity Statin Use in Patients With Nonobstructive Coronary Artery Disease Diagnosed Via Invasive Coronary Angiography. J Am Heart Assoc 2022; 11:e022202. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191316>
 8. Jaltotage B, Gupta A, Ali U *et al.* Coronary computed tomographic angiography derived findings and risk score improves the allocation of lipid lowering therapy compared to clinical score. Medicine (Baltimore) 2022; 101:e28801. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35147115>
 9. To YH, Tan XM, Low CL *et al.* Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score. Singapore medical journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35139626>
 10. Park SY, Rhi SH, Chung JY *et al.* Rapid Regression of Carotid Artery Stenosis Shortly after Intensive Medical Therapy. Tomography 2022; 8:543-549. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35202209>

Atorvastatin/Rosuvastatin

1. Wang D, Tian Y, Wei H *et al.* Risk Factor Analysis of the Conservative Treatment in Chronic Subdural Hematomas: A Substudy of the ATOCH Trial. Adv Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35133631>
2. Fang J, Zhang X. Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris. American journal of translational research 2022; 14:594-602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35173877>
3. Xiong Z, Yi P, Tang X *et al.* Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. BioMed research international 2022; 2022:6747469. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35178452>
4. Zhuang J, Cheng G, Huang J *et al.* Rosuvastatin exerts cardioprotective effect in lipopolysaccharide-mediated injury of cardiomyocytes in an MG53-dependent manner. BMC Cardiovasc Disord 2022; 22:69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35196979>

5. Sung FC, Yeh YT, Muo CH *et al.* Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35159093>
6. Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovascular diabetology 2022; 21:28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193571>
7. Kumar A, Doshi R, Khan SU *et al.* Revascularization or optimal medical therapy for stable ischemic heart disease: A Bayesian meta-analysis of contemporary trials. Cardiovascular revascularization medicine : including molecular interventions 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210188>
8. Groenendaal-van de Meent D, den Adel M, Kerbusch V *et al.* Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies. Clinical pharmacology in drug development 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35182045>
9. McCrea JB, Menzel K, Adedoyin A *et al.* Drug-Drug Interaction of Letemovir and Atorvastatin in Healthy Participants. Clinical pharmacology in drug development 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35157785>
10. Storelli F, Li CY, Sachar M *et al.* Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug. Clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35152400>
11. Murata Y, Isayama R, Imai S *et al.* A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial. Contemporary clinical trials communications 2022; 26:100892. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35198792>
12. Rupasinghe CD, Kantas T, Sani R *et al.* Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial. Cureus 2021; 13:e20710. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35106245>
13. Wagner B, Escobar GP, Jackson DB, DeAguero J. Rosuvastatin-Induced Rhabdomyolysis, Pancreatitis, Transaminitis, and Acute Kidney Injury. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2021; 38:S18-s22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35136340>
14. Cheng T, Li C, Shen L *et al.* The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function. Frontiers in microbiology 2021; 12:797062. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35185821>
15. Lin YS, Lip GYH, Ho WC *et al.* Statins to prevent pacing-induced cardiomyopathy: Evidence from the bench applied to clinical studies. Heart rhythm 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108621>
16. Sultan F, Kaur R, Tarfain NU *et al.* Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF- α expressions affecting oxidative/nitrosative stress and inflammation. Human & experimental toxicology 2022; 41:9603271211066065. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130744>
17. Yerino GA, Feleder EC, Halabe EK *et al.* Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide and rosuvastatin in healthy

- adult subjects. International journal of clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35103587>
18. Motevalian M, Tekyeh Maroof N, Nematollahi MH *et al.* Atorvastatin modulates the expression of aging-related genes in the brain of aging induced by D-galactose in mice. Iranian journal of basic medical sciences 2021; 24:1388-1394. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096297>
 19. Lu E, Hanson C, Beller G, Bourque J. Long-Term Outcomes are Similar Despite Sex Disparities in High-Intensity Statin Use in Patients With Nonobstructive Coronary Artery Disease Diagnosed Via Invasive Coronary Angiography. J Am Heart Assoc 2022; 11:e022202. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191316>
 20. Nedaei H, Rezaei-Ghaleh N, Giller K *et al.* The calcium-free form of atorvastatin inhibits amyloid- β (1-42) aggregation in vitro. The Journal of biological chemistry 2022; 298:101662. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35104501>
 21. Nakajima H, Tsuma Y, Fukuhara S, Kodo K. A Case of Infantile Alagille Syndrome With Severe Dyslipidemia: New Insight into Lipid Metabolism and Therapeutics. Journal of the Endocrine Society 2022; 6:bvac005. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35155971>
 22. Naji MT, Al-Kuraishy HM, Al-Gareeb AI. Differential effects of statins on matrix metalloproteinase-9 (MMP-9) in patients with acute ischaemic stroke: A potential for salutary. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S82-s87. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130225>
 23. Alshaya HA, Alfahad AJ, Alsulaim FM *et al.* Fast-Dissolving Nifedipine and Atorvastatin Calcium Electrospun Nanofibers as a Potential Buccal Delivery System. Pharmaceutics 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35214093>
 24. Leal BH, Velasco B, Cambón A *et al.* Combined Therapeutics for Atherosclerosis Treatment Using Polymeric Nanovectors. Pharmaceutics 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35213991>
 25. Sheikhhassani V, Evers TMJ, Lamba S *et al.* Single cell force spectroscopy of erythrocytes at physiological and febrile temperatures reveals mechano-modulatory effects of atorvastatin. Soft Matter 2022; 18:2143-2148. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35201243>
 26. Park SY, Rhi SH, Chung JY *et al.* Rapid Regression of Carotid Artery Stenosis Shortly after Intensive Medical Therapy. Tomography 2022; 8:543-549. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35202209>
 27. Cai S, Chen Q, Xu Y *et al.* Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. Transl Cancer Res 2020; 9:1439-1447. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35117491>
 28. Yang X, Lan X, Zhang XL *et al.* Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials. World journal of clinical cases 2022; 10:1557-1571. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35211593>

Basic science

1. Rodríguez-Expósito RL, Sifaoui I, Reyes-Batlle M *et al.* Statins Induce Actin Cytoskeleton Disassembly and an Apoptosis-Like Process in *Acanthamoeba* spp. Antibiotics (Basel, Switzerland) 2022; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35203882>
2. Neuparth T, Alves N, Machado AM *et al.* Neuroendocrine pathways at risk? Simvastatin induces inter and transgenerational disruption in the keystone amphipod

- Gammarus locusta. *Aquatic toxicology (Amsterdam, Netherlands)* 2022; 244:106095. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35121565>
3. Kimura A, Kamimura K, Ohkoshi-Yamada M *et al.* Effects of a novel selective PPAR α modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. *Biochem Biophys Res Commun* 2022; 596:76-82. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35121372>
 4. Zhang Q, He J, Xu F *et al.* Correction: Supramolecular copolymer modified statin-loaded discoidal rHDLs for atherosclerotic anti-inflammatory therapy by cholesterol efflux and M2 macrophage polarization. *Biomaterials science* 2022; 10:1594-1595. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35195139>
 5. Maharjan B, Payne DT, Ferrarese I *et al.* Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. *Bioorganic chemistry* 2022; 121:105686. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35217376>
 6. Zhuang J, Cheng G, Huang J *et al.* Rosuvastatin exerts cardioprotective effect in lipopolysaccharide-mediated injury of cardiomyocytes in an MG53-dependent manner. *BMC Cardiovasc Disord* 2022; 22:69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35196979>
 7. de Groot E, Varghese S, Tan L *et al.* Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas. *Cancer Metab* 2022; 10:6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193687>
 8. Semova I, Levenson AE, Krawczyk J *et al.* Insulin Prevents Hypercholesterolemia by Suppressing 12 α -Hydroxylated Bile Acid Production. *Circulation* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193378>
 9. Joseph VMK, Rose EC, Edwards CJ *et al.* Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series. *Clinical and experimental rheumatology* 2022; 40:298-303. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200125>
 10. Sachdeva S, Saluja H, Mani A *et al.* Lipoxins in inflammation. *Clinical hemorheology and microcirculation* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35147530>
 11. Storelli F, Li CY, Sachar M *et al.* Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug. *Clinical pharmacology and therapeutics* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35152400>
 12. Yang J, Sun M, Cheng R *et al.* Pitavastatin activates mitophagy to protect EPC proliferation through a calcium-dependent CAMK1-PINK1 pathway in atherosclerotic mice. *Commun Biol* 2022; 5:124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35145192>
 13. Verma K, Makwana S, Paliwal S *et al.* Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidemic rats. *Curr Res Pharmacol Drug Discov* 2022; 3:100088. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35146420>
 14. Kuşçu GC, Gürel Ç, Buhur A *et al.* Fluvastatin alleviates doxorubicin-induced cardiac and renal toxicity in rats via regulation of oxidative stress, inflammation, and apoptosis associated genes expressions. *Drug and chemical toxicology* 2022:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209778>
 15. Cheng T, Li C, Shen L *et al.* The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function. *Frontiers in microbiology* 2021; 12:797062. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35185821>

16. Rizg WY, Naveen NR, Kurakula M *et al.* QbD Supported Optimization of the Alginate-Chitosan Nanoparticles of Simvastatin in Enhancing the Anti-Proliferative Activity against Tongue Carcinoma. Gels 2022; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200484>
17. Saraogi GK, Tholiya S, Mishra Y *et al.* Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management. Gels 2022; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200462>
18. Sultan F, Kaur R, Tarfain NU *et al.* Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF- α expressions affecting oxidative/nitrosative stress and inflammation. Human & experimental toxicology 2022; 41:9603271211066065. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130744>
19. Bourg N, Vu Hong A, Lostal W *et al.* Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy. Int J Mol Sci 2022; 23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35216132>
20. Grunwald SA, Haafke S, Grieben U *et al.* Statins Aggravate the Risk of Insulin Resistance in Human Muscle. Int J Mol Sci 2022; 23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35216514>
21. Alayoubi A, Zidan A, Asfari S *et al.* Mechanistic understanding of the performance of personalized 3D-printed cardiovascular polypills: A case study of patient-centered therapy. Int J Pharm 2022; 617:121599. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35182706>
22. Bruinsmann FA, de Cristo Soares Alves A, de Fraga Dias A *et al.* Nose-to-brain delivery of simvastatin mediated by chitosan-coated lipid-core nanocapsules allows for the treatment of glioblastoma in vivo. Int J Pharm 2022; 616:121563. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35151819>
23. Motevalian M, Tekyeh Maroof N, Nematollahi MH *et al.* Atorvastatin modulates the expression of aging-related genes in the brain of aging induced by D-galactose in mice. Iranian journal of basic medical sciences 2021; 24:1388-1394. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096297>
24. Nedaei H, Rezaei-Ghaleh N, Giller K *et al.* The calcium-free form of atorvastatin inhibits amyloid- β (1-42) aggregation in vitro. The Journal of biological chemistry 2022; 298:101662. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35104501>
25. Afrin S, Ali M, El Sabeh M *et al.* Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF- β 3 and Wnt/ β -Catenin pathways. Journal of cellular and molecular medicine 2022; 26:1684-1698. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35118811>
26. Hamdy MMA, Korany MA, Ebied SA, Haggag RS. Stability-indicating RP-HPLC assay of three novel oral anticoagulants binary mixtures with rosuvastatin calcium: Application to pharmaceutical preparations and human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2022; 1193:123160. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35189581>
27. El Sabeh M, Vincent KL, Afrin S *et al.* Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study. J Obstet Gynaecol 2022:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35166183>
28. Yuan X, Yuan Z, Wang Y *et al.* Vascularized pulp regeneration via injecting simvastatin functionalized GelMA cryogel microspheres loaded with stem cells from human exfoliated deciduous teeth. Mater Today Bio 2022; 13:100209. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35198958>

29. Jun JH, Oh KC, Park KH *et al.* Correction: Jun *et al.* Improvement of Osseointegration by Ultraviolet and/or Simvastatin Treatment on Titanium Implants with or without Bone Graft Materials. *Materials* 2021, 14, 3707. *Materials* (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35208162>
30. Srinivasan N, Thangavelu K, Uthandi S. Lovastatin production by an oleaginous fungus, *Aspergillus terreus* KPR12 using sago processing wastewater (SWW). *Microb Cell Fact* 2022; 21:22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35164756>
31. Fujii TTS, Gomes PS, do Monte-Neto RL *et al.* Simvastatin Resistance of *Leishmania amazonensis* Induces Sterol Remodeling and Cross-Resistance to Sterol Pathway and Serine Protease Inhibitors. *Microorganisms* 2022; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35208853>
32. Brus J, Czernek J, Urbanova M, Červinka C. Enantiotropy of Simvastatin as a Result of Weakened Interactions in the Crystal Lattice: Entropy-Driven Double Transitions and the Transient Modulated Phase as Seen by Solid-State NMR Spectroscopy. *Molecules* (Basel, Switzerland) 2022; 27. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35163943>
33. Pulgar VM, Cruz-Diaz N, Westwood BM, Chappell MC. Angiotensinogen uptake and stimulation of oxidative stress in human pigment retinal epithelial cells. *Peptides* 2022; 152:170770. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35183655>
34. Liang R, Ge W, Li B *et al.* Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs. *Pharmaceutical biology* 2022; 60:359-373. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35171063>
35. Kobayashi Y, Takeda T, Kunitomi H *et al.* Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. *Pharmaceuticals* (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215239>
36. Alshaya HA, Alfahad AJ, Alsulaim FM *et al.* Fast-Dissolving Nifedipine and Atorvastatin Calcium Electrospun Nanofibers as a Potential Buccal Delivery System. *Pharmaceutics* 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35214093>
37. Leal BH, Velasco B, Cambón A *et al.* Combined Therapeutics for Atherosclerosis Treatment Using Polymeric Nanovectors. *Pharmaceutics* 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35213991>
38. Sheikhhassani V, Evers TMJ, Lamba S *et al.* Single cell force spectroscopy of erythrocytes at physiological and febrile temperatures reveals mechano-modulatory effects of atorvastatin. *Soft Matter* 2022; 18:2143-2148. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35201243>
39. Cai S, Chen Q, Xu Y *et al.* Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. *Transl Cancer Res* 2020; 9:1439-1447. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35117491>

Cancer

1. de Groot E, Varghese S, Tan L *et al.* Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas. *Cancer Metab* 2022; 10:6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193687>
2. Sung FC, Yeh YT, Muo CH *et al.* Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. *Cancers* 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35159093>

3. Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35158055>
4. Gohlke BO, Zincke F, Eckert A *et al.* Real-world evidence for preventive effects of statins on cancer incidence: A trans-Atlantic analysis. Clinical and translational medicine 2022; 12:e726. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184411>
5. Heiston EM, Hundley WG. Statins for Cardiac and Vascular Protection During and After Cancer Therapy. Curr Oncol Rep 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199294>
6. Kuşçu GC, Gürel Ç, Buhur A *et al.* Fluvastatin alleviates doxorubicin-induced cardiac and renal toxicity in rats via regulation of oxidative stress, inflammation, and apoptosis associated genes expressions. Drug and chemical toxicology 2022;1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209778>
7. Rendon LF, Tewarie IA, Cote DJ *et al.* Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature. Drugs 2022; 82:293-310. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35122635>
8. Rizg WY, Naveen NR, Kurakula M *et al.* QbD Supported Optimization of the Alginate-Chitosan Nanoparticles of Simvastatin in Enhancing the Anti-Proliferative Activity against Tongue Carcinoma. Gels 2022; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200484>
9. Bruinsmann FA, de Cristo Soares Alves A, de Fraga Dias A *et al.* Nose-to-brain delivery of simvastatin mediated by chitosan-coated lipid-core nanocapsules allows for the treatment of glioblastoma in vivo. Int J Pharm 2022; 616:121563. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35151819>
10. Afrin S, Ali M, El Sabeh M *et al.* Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF- β 3 and Wnt/ β -Catenin pathways. Journal of cellular and molecular medicine 2022; 26:1684-1698. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35118811>
11. Hou YC, Shao YH. The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215243>
12. Kobayashi Y, Takeda T, Kunitomi H *et al.* Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. Pharmaceuticals (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215239>
13. Cai S, Chen Q, Xu Y *et al.* Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. Transl Cancer Res 2020; 9:1439-1447. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35117491>
14. Uemura N, Hayashi H, Baba H. Statin as a therapeutic agent in gastroenterological cancer. World J Gastrointest Oncol 2022; 14:110-123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35116106>

Children

1. Sanin V, Schmieder R, Ates S *et al.* Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165720>
2. Wong C, Chu P, Teoh J *et al.* Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre

cohort study. International urology and nephrology 2022.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=35217907>

Cost-effectiveness

1. Weintraub WS, Bhatt DL, Zhang Z *et al.* Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA network open 2022; 5:e2148172. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35157055>

CVD

1. Verma KP, Marwick T, Duarte C *et al.* Use of Coronary Computed Tomography or Polygenic Risk Scores to Prompt Action to Reduce Coronary Artery Disease Risk: The CAPAR-CAD Trial. Am Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218726>
2. Dykun I, Bayturan O, Carlo J *et al.* HbA1c, Coronary atheroma progression and cardiovascular outcomes. Am J Prev Cardiol 2022; 9:100317. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112095>
3. Wagner JR, Fitzpatrick JK, Yang J *et al.* Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study. Am J Prev Cardiol 2022; 9:100319. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199077>
4. Fang J, Zhang X. Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris. American journal of translational research 2022; 14:594-602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35173877>
5. Zhang Y, Zhao X, Ding X *et al.* Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L. Angiology 2022:33197221075861. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191328>
6. Al Abbasi B, Borzak S. In patients with stable CVD receiving statins, evolocumab reduced acute arterial events across all vascular territories. Annals of internal medicine 2022; 175:Jc14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35100002>
7. Baharudin N, Mohamed-Yassin MS, Daher AM *et al.* Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study. BMC public health 2022; 22:228. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35120488>
8. Zhang L, Wang W, Man F *et al.* The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome. Cardiovasc Drugs Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35138504>
9. Kumar A, Doshi R, Khan SU *et al.* Revascularization or optimal medical therapy for stable ischemic heart disease: A Bayesian meta-analysis of contemporary trials. Cardiovascular revascularization medicine : including molecular interventions 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210188>
10. Furtado RHM, Fagundes AA, Jr., Oyama K *et al.* Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation. Cardiovascular interventions 2022; 15:e011382. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209731>
11. Heiston EM, Hundley WG. Statins for Cardiac and Vascular Protection During and After Cancer Therapy. Curr Oncol Rep 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199294>
12. Ishii M, Kuramitsu S, Yamanaga K *et al.* Association of Guideline-Directed Medical Therapy Adherence with Outcomes After Fractional Flow Reserve-Based Deferral of

- Revascularization. European heart journal. Cardiovascular pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108383>
13. Norberg H, Sjölander M, Glader EL, Gustafsson M. Self-reported medication adherence and pharmacy refill adherence among persons with ischemic stroke: a cross-sectional study. Eur J Clin Pharmacol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35156130>
 14. Petraglia L, Conte M, Comentale G *et al.* Epicardial Adipose Tissue and Postoperative Atrial Fibrillation. Frontiers in cardiovascular medicine 2022; 9:810334. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35187125>
 15. Yao Y, Li X, Wang Z *et al.* Interaction of Lipids, Mean Platelet Volume, and the Severity of Coronary Artery Disease Among Chinese Adults: A Mediation Analysis. Frontiers in cardiovascular medicine 2022; 9:753171. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35174229>
 16. Zuo HJ, Nan N, Yang HX *et al.* Impact of Conventional Cardiovascular Risk Factors on Left Internal Mammary Artery Graft Disease. Frontiers in cardiovascular medicine 2021; 8:705765. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096986>
 17. Sultan F, Kaur R, Tarfain NU *et al.* Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF- α expressions affecting oxidative/nitrosative stress and inflammation. Human & experimental toxicology 2022; 41:9603271211066065. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130744>
 18. Abbasifard M, Kandelouei T, Aslani S *et al.* Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials. Inflammopharmacology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165809>
 19. Yi SW, An SJ, Park HB *et al.* Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. International journal of epidemiology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218344>
 20. Nguy J, Hitchen SA, Lan NSR *et al.* Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation. Internal medicine journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112773>
 21. Lu E, Hanson C, Beller G, Bourque J. Long-Term Outcomes are Similar Despite Sex Disparities in High-Intensity Statin Use in Patients With Nonobstructive Coronary Artery Disease Diagnosed Via Invasive Coronary Angiography. J Am Heart Assoc 2022; 11:e022202. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191316>
 22. Xu Y, Guo S, Jiang H *et al.* Collateral Status and Clinical Outcomes after Mechanical Thrombectomy in Patients with Anterior Circulation Occlusion. J Healthc Eng 2022; 2022:7796700. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35126946>
 23. Afanasieva OI, Tyurina AV, Klesareva EA *et al.* Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease. Journal of personalized medicine 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35207757>
 24. Marcus ME, Manne-Goehler J, Theilmann M *et al.* Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. The Lancet. Global health 2022; 10:e369-e379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180420>
 25. Raal FJ, Mohamed F. Statins: are they appropriate for all patients? The Lancet. Global health 2022; 10:e305-e306. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180403>
 26. Kandelouei T, Abbasifard M, Imani D *et al.* Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-

Analysis of Randomized Controlled Trials. Mediators Inflamm 2022; 2022:8732360. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125965>

27. Zou X, Nie L, Liao Y *et al.* Effects of statin therapy and treatment duration on cardiovascular disease risk in patients with nephrotic syndrome: A nested case-control study. Pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184315>
28. To YH, Tan XM, Low CL *et al.* Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score. Singapore medical journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35139626>
29. Yang X, Lan X, Zhang XL *et al.* Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials. World journal of clinical cases 2022; 10:1557-1571. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35211593>

Endothelium/inflammation

1. Mazurek A, Gryga K, Bugala K *et al.* Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus. Archives of medical science : AMS 2022; 18:18-24. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35154521>
2. Zhang Q, He J, Xu F *et al.* Correction: Supramolecular copolymer modified statin-loaded discoidal rHDLs for atherosclerotic anti-inflammatory therapy by cholesterol efflux and M2 macrophage polarization. Biomaterials science 2022; 10:1594-1595. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35195139>
3. Sachdeva S, Saluja H, Mani A *et al.* Lipoxins in inflammation. Clinical hemorheology and microcirculation 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35147530>
4. Abbasifard M, Kandelouei T, Aslani S *et al.* Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials. Inflammopharmacology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165809>
5. Kandelouei T, Abbasifard M, Imani D *et al.* Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm 2022; 2022:8732360. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125965>

Ethnicity

1. Fang J, Zhang X. Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris. American journal of translational research 2022; 14:594-602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35173877>
2. Zhang Y, Zhao X, Ding X *et al.* Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L. Angiology 2022;33197221075861. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191328>
3. Abed W, Abujbara M, Batieha A, Ajlouni K. Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. Annals of medicine and surgery (2012) 2022; 74:103304. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35145672>
4. Kim S, Choi H, Won CW. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and

- older. Archives of gerontology and geriatrics 2022; 100:104644. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35121242>
5. Baharudin N, Mohamed-Yassin MS, Daher AM *et al.* Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study. BMC public health 2022; 22:228. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35120488>
 6. Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovascular diabetology 2022; 21:28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193571>
 7. Zhang L, Wang W, Man F *et al.* The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome. Cardiovasc Drugs Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35138504>
 8. Murata Y, Isayama R, Imai S *et al.* A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial. Contemporary clinical trials communications 2022; 26:100892. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35198792>
 9. Yang SY, Hwang HJ. Does diabetes increase the risk of cardiovascular events in patients with negative treadmill stress echocardiography? Endocrine journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125378>
 10. Ishii M, Kuramitsu S, Yamanaga K *et al.* Association of Guideline-Directed Medical Therapy Adherence with Outcomes After Fractional Flow Reserve-Based Deferral of Revascularization. European heart journal. Cardiovascular pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108383>
 11. Huh JH, Park SW, Go TH *et al.* Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea. Frontiers in cardiovascular medicine 2021; 8:812416. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35127872>
 12. Park JB, Shin E, Lee JE *et al.* Genetic Determinants of Visit-to-Visit Lipid Variability: Genome-Wide Association Study in Statin-Naïve Korean Population. Frontiers in cardiovascular medicine 2022; 9:811657. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35174233>
 13. Yao Y, Li X, Wang Z *et al.* Interaction of Lipids, Mean Platelet Volume, and the Severity of Coronary Artery Disease Among Chinese Adults: A Mediation Analysis. Frontiers in cardiovascular medicine 2022; 9:753171. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35174229>
 14. Lin YS, Lip GYH, Ho WC *et al.* Statins to prevent pacing-induced cardiomyopathy: Evidence from the bench applied to clinical studies. Heart rhythm 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108621>
 15. Yi SW, An SJ, Park HB *et al.* Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. International journal of epidemiology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218344>
 16. Wong C, Chu P, Teoh J *et al.* Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study. International urology and nephrology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35217907>
 17. Ying Q, Chan DC, Pang J *et al.* PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients

- with very high apolipoprotein(a) concentration. Journal of internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112754>
18. Chen YY, Li TC, Li CI *et al.* Statins Associated with Better Long-Term Outcomes in Aged Hospitalized Patients with COPD: A Real-World Experience from Pay-for-Performance Program. Journal of personalized medicine 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35207787>
 19. Marcus ME, Manne-Goehler J, Theilmann M *et al.* Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. The Lancet. Global health 2022; 10:e369-e379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180420>
 20. Raal FJ, Mohamed F. Statins: are they appropriate for all patients? The Lancet. Global health 2022; 10:e305-e306. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180403>
 21. Jithesh PV, Abuhaliqa M, Syed N *et al.* A population study of clinically actionable genetic variation affecting drug response from the Middle East. NPJ Genom Med 2022; 7:10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35169154>
 22. Jeong W, Joo JH, Kim H *et al.* Association between statin adherence and the risk of stroke among South Korean adults with hyperlipidemia. Nutrition, metabolism, and cardiovascular diseases : NMCD 2022; 32:560-566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35105503>
 23. Vanwong N, Tipnoppanon S, Na Nakorn C *et al.* Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. Pharmacogenomics and personalized medicine 2022; 15:119-130. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210819>
 24. Yang X, Lan X, Zhang XL *et al.* Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials. World journal of clinical cases 2022; 10:1557-1571. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35211593>

FH

1. Lindell OP, Karlsson LO, Nilsson S *et al.* Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care. Am Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35181275>
2. Chlebus K, Cybulska B, Dobrowolski P *et al.* Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data. Cardiology journal 2022; 29:62-71. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35146730>
3. Wei N, Hu Y, Liu G *et al.* A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021. Curr Probl Cardiol 2022:101151. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35202707>
4. Reijman MD, Schweizer A, Peterson ALH *et al.* Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175352>
5. Sanin V, Schmieder R, Ates S *et al.* Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165720>
6. Silva PRS, Jannes CE, Oliveira TGM *et al.* Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. J Clin Lipidol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35181259>

7. Bangash H, Makkawy A, Gundelach JH *et al.* Web-Based Tool (FH Family Share) to Increase Uptake of Cascade Testing for Familial Hypercholesterolemia: Development and Evaluation. JMIR human factors 2022; 9:e32568. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35166678>

Genetics

1. Park JB, Shin E, Lee JE *et al.* Genetic Determinants of Visit-to-Visit Lipid Variability: Genome-Wide Association Study in Statin-Naïve Korean Population. Frontiers in cardiovascular medicine 2022; 9:811657. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35174233>
2. Nakajima H, Tsuma Y, Fukuhara S, Kodo K. A Case of Infantile Alagille Syndrome With Severe Dyslipidemia: New Insight into Lipid Metabolism and Therapeutics. Journal of the Endocrine Society 2022; 6:bvac005. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35155971>
3. Mehta C, Cohen D, Jaisinghani P, Parikh P. Internal Medicine Resident Adherence to Evidence-Based Practices in Management of Diabetes Mellitus. J Med Educ Curric Dev 2022; 9:23821205221076659. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35128060>
4. Lin Y, Yang Q, Liu Z *et al.* Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease. Molecules (Basel, Switzerland) 2022; 27. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209166>
5. Jithesh PV, Abuhaliqa M, Syed N *et al.* A population study of clinically actionable genetic variation affecting drug response from the Middle East. NPJ Genom Med 2022; 7:10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35169154>
6. Vanwong N, Tipnoppanon S, Na Nakorn C *et al.* Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. Pharmacogenomics and personalized medicine 2022; 15:119-130. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210819>

Guidelines

1. Chi CL, Wang J, Ying Yew P *et al.* Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning. J Biomed Inform 2022; 128:104029. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35182785>
2. Silva PRS, Jannes CE, Oliveira TGM *et al.* Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. J Clin Lipidol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35181259>
3. Nelson AJ, O'Brien EC, Kaltenbach LA *et al.* Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA network open 2022; 5:e2148030. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175345>
4. Marcus ME, Manne-Goehler J, Theilmann M *et al.* Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. The Lancet. Global health 2022; 10:e369-e379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180420>
5. Raal FJ, Mohamed F. Statins: are they appropriate for all patients? The Lancet. Global health 2022; 10:e305-e306. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180403>

LDL- related parameters

1. Zhang Y, Zhao X, Ding X *et al.* Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L. Angiology 2022;33197221075861. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191328>
2. Siudut J, Natorska J, Wypasek E *et al.* Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis. Atherosclerosis 2022; 344:49-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35134656>
3. Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovascular diabetology 2022; 21:28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193571>
4. Semova I, Levenson AE, Krawczyk J *et al.* Insulin Prevents Hypercholesterolemia by Suppressing 12 α -Hydroxylated Bile Acid Production. Circulation 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193378>
5. Rupasinghe CD, Kantas T, Sani R *et al.* Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial. Cureus 2021; 13:e20710. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35106245>
6. Ishii M, Kuramitsu S, Yamanaga K *et al.* Association of Guideline-Directed Medical Therapy Adherence with Outcomes After Fractional Flow Reserve-Based Deferral of Revascularization. European heart journal. Cardiovascular pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108383>
7. Ray KK, Dhalwani N, Sibartie M *et al.* Low density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. European heart journal. Quality of care & clinical outcomes 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175350>
8. Huh JH, Park SW, Go TH *et al.* Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea. Frontiers in cardiovascular medicine 2021; 8:812416. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35127872>
9. Park JB, Shin E, Lee JE *et al.* Genetic Determinants of Visit-to-Visit Lipid Variability: Genome-Wide Association Study in Statin-Naïve Korean Population. Frontiers in cardiovascular medicine 2022; 9:811657. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35174233>
10. Yao Y, Liu J, Wang B *et al.* Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients. Frontiers in cardiovascular medicine 2021; 8:817442. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35097030>
11. Zuo HJ, Nan N, Yang HX *et al.* Impact of Conventional Cardiovascular Risk Factors on Left Internal Mammary Artery Graft Disease. Frontiers in cardiovascular medicine 2021; 8:705765. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096986>
12. Yi SW, An SJ, Park HB *et al.* Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. International journal of epidemiology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218344>
13. Wong C, Chu P, Teoh J *et al.* Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study. International urology and nephrology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35217907>

14. Trinder M, Paruchuri K, Haidermota S *et al.* Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. J Am Coll Cardiol 2022; 79:617-628. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35177190>
15. Tsimikas S. Lipoprotein(a) and Coronary Calcium: Clinical Management and Potential Design of Primary Prevention Trials. J Am Coll Cardiol 2022; 79:769-771. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210031>
16. Chi CL, Wang J, Ying Yew P *et al.* Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning. J Biomed Inform 2022; 128:104029. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35182785>
17. Silva PRS, Jannes CE, Oliveira TGM *et al.* Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. J Clin Lipidol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35181259>
18. Ying Q, Chan DC, Pang J *et al.* PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration. Journal of internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112754>
19. Mehta C, Cohen D, Jaisinghani P, Parikh P. Internal Medicine Resident Adherence to Evidence-Based Practices in Management of Diabetes Mellitus. J Med Educ Curric Dev 2022; 9:23821205221076659. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35128060>
20. Afanasieva OI, Tyurina AV, Klesareva EA *et al.* Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease. Journal of personalized medicine 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35207757>
21. Nelson AJ, O'Brien EC, Kaltenbach LA *et al.* Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA network open 2022; 5:e2148030. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175345>
22. Lee M, Cheng CY, Wu YL *et al.* Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA neurology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188949>
23. Lin Y, Yang Q, Liu Z *et al.* Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease. Molecules (Basel, Switzerland) 2022; 27. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209166>
24. Jithesh PV, Abuhaliqa M, Syed N *et al.* A population study of clinically actionable genetic variation affecting drug response from the Middle East. NPJ Genom Med 2022; 7:10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35169154>
25. Vanwong N, Tipnoppanon S, Na Nakorn C *et al.* Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. Pharmacogenomics and personalized medicine 2022; 15:119-130. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210819>
26. Yang X, Lan X, Zhang XL *et al.* Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials. World journal of clinical cases 2022; 10:1557-1571. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35211593>

Meta-analyses

1. Kumar A, Doshi R, Khan SU *et al.* Revascularization or optimal medical therapy for stable ischemic heart disease: A Bayesian meta-analysis of contemporary trials.

- Cardiovascular revascularization medicine : including molecular interventions 2021.**
<http://www.ncbi.nlm.nih.gov/pubmed/?term=35210188>
2. Rendon LF, Tewarie IA, Cote DJ *et al.* Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature. Drugs 2022; 82:293-310. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35122635>
 3. Bytyçi I, Penson PE, Mikhailidis DP *et al.* Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35169843>
 4. Abbasifard M, Kandelouei T, Aslani S *et al.* Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials. Inflammopharmacology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165809>
 5. Cui C, Li Q, Li C *et al.* Statin pretreatment combined with intravenous thrombolysis for ischemic stroke patients: A meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; 98:142-148. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180504>
 6. Lee M, Cheng CY, Wu YL *et al.* Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA neurology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188949>
 7. Kandelouei T, Abbasifard M, Imani D *et al.* Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm 2022; 2022:8732360. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125965>
 8. Stefanou MI, Palaiodimou L, Katsanos AH *et al.* The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis. Multiple sclerosis and related disorders 2022; 58:103395. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35216778>
 9. Hou YC, Shao YH. The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215243>
 10. Li Z, Li Y, Li X *et al.* Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2022; 33:136-144. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35115293>
 11. Yang X, Lan X, Zhang XL *et al.* Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials. World journal of clinical cases 2022; 10:1557-1571. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35211593>

Metabolic Syndrome - Diabetes

1. Rosenberg K. Statin Use Associated with Diabetes Progression. The American journal of nursing 2022; 122:45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200187>
2. Dykun I, Bayturan O, Carlo J *et al.* HbA1c, Coronary atheroma progression and cardiovascular outcomes. Am J Prev Cardiol 2022; 9:100317. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112095>
3. Brailovski E, Li Q, Liu N *et al.* The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of hematology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35190844>

4. Ozen G, Dell'Aniello S, Pedro S *et al.* Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis. Arthritis care & research 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35119769>
5. Croyal M, Wargny M, Chemello K *et al.* Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovascular diabetology 2022; 21:21. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130909>
6. Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovascular diabetology 2022; 21:28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193571>
7. Semova I, Levenson AE, Krawczyk J *et al.* Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production. Circulation 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193378>
8. Yang SY, Hwang HJ. Does diabetes increase the risk of cardiovascular events in patients with negative treadmill stress echocardiography? Endocrine journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125378>
9. Zuo HJ, Nan N, Yang HX *et al.* Impact of Conventional Cardiovascular Risk Factors on Left Internal Mammary Artery Graft Disease. Frontiers in cardiovascular medicine 2021; 8:705765. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096986>
10. Grunwald SA, Haafke S, Grieben U *et al.* Statins Aggravate the Risk of Insulin Resistance in Human Muscle. Int J Mol Sci 2022; 23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35216514>
11. Mehta C, Cohen D, Jaisinghani P, Parikh P. Internal Medicine Resident Adherence to Evidence-Based Practices in Management of Diabetes Mellitus. J Med Educ Curric Dev 2022; 9:23821205221076659. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35128060>
12. Ganatra RB, Bhatnagar A, Herzig SJ. Strengthening a Study of Diabetes Progression After Statin Use. JAMA Intern Med 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188529>
13. Mansi IA, Lingvay I, Alvarez CA. Strengthening a Study of Diabetes Progression After Statin Use-Reply. JAMA Intern Med 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188526>
14. Nelson AJ, O'Brien EC, Kaltenbach LA *et al.* Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA network open 2022; 5:e2148030. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175345>

New Treatments

1. Al Abbasi B, Borzak S. In patients with stable CVD receiving statins, evolocumab reduced acute arterial events across all vascular territories. Annals of internal medicine 2022; 175:Jc14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35100002>
2. Maharjan B, Payne DT, Ferrarese I *et al.* Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. Bioorganic chemistry 2022; 121:105686. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35217376>
3. Chlebus K, Cybulska B, Dobrowolski P *et al.* Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic

- program in Poland: Preliminary multicenter data. Cardiology journal 2022; 29:62-71. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35146730>
4. Furtado RHM, Fagundes AA, Jr., Oyama K *et al.* Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation. Cardiovascular interventions 2022; 15:e011382. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209731>
 5. Ray KK, Dhalwani N, Sibartie M *et al.* Low density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. European heart journal. Quality of care & clinical outcomes 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175350>
 6. Reijman MD, Schweizer A, Peterson ALH *et al.* Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175352>
 7. Imarhia FI, Sulaica EM, Varisco T, Pilate M. Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2021; 38:e67-e71. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35136343>
 8. Nguy J, Hitchen SA, Lan NSR *et al.* Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation. Internal medicine journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112773>
 9. Silva PRS, Jannes CE, Oliveira TGM *et al.* Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. J Clin Lipidol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35181259>
 10. Ying Q, Chan DC, Pang J *et al.* PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration. Journal of internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35112754>
 11. Scheen AJ, Paquot N, Wallemacq C. (Bempedoic acid, new cholesterol-lowering drug). Revue medicale de Liege 2022; 77:124-131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35143133>

Other

1. Esfehni RJ, Vojdanparast M, Soleimanpour S *et al.* The Potential Impact of Statins in the Treatment of Patients with COVID-19 Infection. Advances in experimental medicine and biology 2021; 1352:149-158. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35132599>
2. Smati S, Tramunt B, Wargny M *et al.* COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. Current diabetes reports 2022; 22:53-63. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35171448>
3. Petraglia L, Conte M, Comentale G *et al.* Epicardial Adipose Tissue and Postoperative Atrial Fibrillation. Frontiers in cardiovascular medicine 2022; 9:810334. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35187125>
4. Hussien NR, Al-Niemi MS, Al-Kuraishy HM, Al-Gareeb AI. Statins and Covid-19: The Neglected Front of bidirectional effects. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S133-s136. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130236>
5. Hammad EA, Al-Aqeel S, Elayah E, Jaber D. Assessing content and factors influencing responses to information requests in community pharmacies in Jordan:

A simulated patients study. PLoS One 2022; 17:e0264224.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=35180273>

PAD and statins

1. Zil EAA, Medina D, Orozco D *et al.* Preoperative Statin Use is Associated With Lower Incidence of Limb Loss After Lower Extremity Endovascular Interventions. The American surgeon 2022;31348211068000. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35166610>
2. Adamičková A, Gažová A, Adamička M *et al.* Molecular basis of the effect of atorvastatin pretreatment on stem cell therapy in chronic ischemic diseases - critical limb ischemia. Physiological research / Academia Scientiarum Bohemoslovaca 2021; 70:S527-s533. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199541>

Pleiotropic effects of statins

1. Mazurek A, Gryga K, Bugala K *et al.* Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus. Archives of medical science : AMS 2022; 18:18-24. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35154521>
2. Kimura A, Kamimura K, Ohkoshi-Yamada M *et al.* Effects of a novel selective PPAR α modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. Biochem Biophys Res Commun 2022; 596:76-82. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35121372>
3. Xiong Z, Yi P, Tang X *et al.* Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. BioMed research international 2022; 2022:6747469. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35178452>
4. Zhuang J, Cheng G, Huang J *et al.* Rosuvastatin exerts cardioprotective effect in lipopolysaccharide-mediated injury of cardiomyocytes in an MG53-dependent manner. BMC Cardiovasc Disord 2022; 22:69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35196979>
5. de Groot E, Varghese S, Tan L *et al.* Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas. Cancer Metab 2022; 10:6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193687>
6. Sung FC, Yeh YT, Muo CH *et al.* Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35159093>
7. Rinella ME, Satapathy SK, Brandman D *et al.* Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35189388>
8. Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35158055>

9. Yang J, Sun M, Cheng R *et al.* Pitavastatin activates mitophagy to protect EPC proliferation through a calcium-dependent CAMK1-PINK1 pathway in atherosclerotic mice. Commun Biol 2022; 5:124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35145192>
10. Murata Y, Isayama R, Imai S *et al.* A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial. Contemporary clinical trials communications 2022; 26:100892. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35198792>
11. Santacruz JC, Mantilla MJ, Rueda I *et al.* Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist. Cureus 2022; 14:e21090. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165550>
12. Verma K, Makwana S, Paliwal S *et al.* Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidemic rats. Curr Res Pharmacol Drug Discov 2022; 3:100088. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35146420>
13. Kuşçu GC, Gürel Ç, Buhur A *et al.* Fluvastatin alleviates doxorubicin-induced cardiac and renal toxicity in rats via regulation of oxidative stress, inflammation, and apoptosis associated genes expressions. Drug and chemical toxicology 2022:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35209778>
14. Rendon LF, Tewarie IA, Cote DJ *et al.* Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature. Drugs 2022; 82:293-310. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35122635>
15. Petraglia L, Conte M, Comentale G *et al.* Epicardial Adipose Tissue and Postoperative Atrial Fibrillation. Frontiers in cardiovascular medicine 2022; 9:810334. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35187125>
16. Cheng T, Li C, Shen L *et al.* The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function. Frontiers in microbiology 2021; 12:797062. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35185821>
17. Rizg WY, Naveen NR, Kurakula M *et al.* QbD Supported Optimization of the Alginate-Chitosan Nanoparticles of Simvastatin in Enhancing the Anti-Proliferative Activity against Tongue Carcinoma. Gels 2022; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200484>
18. Whitlon DS. Statins and hearing. Hear Res 2022:108453. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125240>
19. Lin YS, Lip GYH, Ho WC *et al.* Statins to prevent pacing-induced cardiomyopathy: Evidence from the bench applied to clinical studies. Heart rhythm 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35108621>
20. Sultan F, Kaur R, Tarfain NU *et al.* Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF- α expressions affecting oxidative/nitrosative stress and inflammation. Human & experimental toxicology 2022; 41:9603271211066065. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130744>
21. Abbasifard M, Kandelouei T, Aslani S *et al.* Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials. Inflammopharmacology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165809>
22. Anagnostis P, Florentin M, Livadas S *et al.* Bone Health in Patients with Dyslipidemias: An Underestimated Aspect. Int J Mol Sci 2022; 23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35163560>
23. Bruinsmann FA, de Cristo Soares Alves A, de Fraga Dias A *et al.* Nose-to-brain delivery of simvastatin mediated by chitosan-coated lipid-core nanocapsules allows for the treatment of glioblastoma in vivo. Int J Pharm 2022; 616:121563. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35151819>

24. Motevalian M, Tekyeh Maroof N, Nematollahi MH *et al.* Atorvastatin modulates the expression of aging-related genes in the brain of aging induced by D-galactose in mice. Iranian journal of basic medical sciences 2021; 24:1388-1394. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35096297>
25. Nedaei H, Rezaei-Ghaleh N, Giller K *et al.* The calcium-free form of atorvastatin inhibits amyloid- β (1-42) aggregation in vitro. The Journal of biological chemistry 2022; 298:101662. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35104501>
26. Afrin S, Ali M, El Sabeh M *et al.* Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF- β 3 and Wnt/ β -Catenin pathways. Journal of cellular and molecular medicine 2022; 26:1684-1698. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35118811>
27. Mazard T, Ritzenthaler T, Dailler F. Pravastatin may improve neurological outcome following low-grade aneurysmal subarachnoid hemorrhage. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; 98:11-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35131719>
28. Santos AN, Rauschenbach L, Saban D *et al.* Medication intake and hemorrhage risk in patients with familial cerebral cavernous malformations. Journal of neurosurgery 2022:1-7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35213840>
29. El Sabeh M, Vincent KL, Afrin S *et al.* Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study. J Obstet Gynaecol 2022:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35166183>
30. Al-Rubiay HF, Al-Kuraishy HM, Al-Gareeb AI. Intercellular adhesive molecule 1(ICAM-1) and acute ischaemic stroke: Role of statins. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S11-s16. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130210>
31. Naji MT, Al-Kuraishy HM, Al-Gareeb AI. Differential effects of statins on matrix metalloproteinase-9 (MMP-9) in patients with acute ischaemic stroke: A potential for salutary. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S82-s87. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130225>
32. Chen YY, Li TC, Li CI *et al.* Statins Associated with Better Long-Term Outcomes in Aged Hospitalized Patients with COPD: A Real-World Experience from Pay-for-Performance Program. Journal of personalized medicine 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35207787>
33. Abu El Hawa AA, Klein D, Bekeny JC *et al.* The impact of statins on wound healing: an ally in treating the highly comorbid patient. J Wound Care 2022; 31:S36-s41. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35148640>
34. Yuan X, Yuan Z, Wang Y *et al.* Vascularized pulp regeneration via injecting simvastatin functionalized GelMA cryogel microspheres loaded with stem cells from human exfoliated deciduous teeth. Mater Today Bio 2022; 13:100209. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35198958>
35. Jun JH, Oh KC, Park KH *et al.* Correction: Jun *et al.* Improvement of Osseointegration by Ultraviolet and/or Simvastatin Treatment on Titanium Implants with or without Bone Graft Materials. Materials 2021, 14, 3707. Materials (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35208162>
36. Fujii TTS, Gomes PS, do Monte-Neto RL *et al.* Simvastatin Resistance of *Leishmania amazonensis* Induces Sterol Remodeling and Cross-Resistance to Sterol Pathway and Serine Protease Inhibitors. Microorganisms 2022; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35208853>
37. Goodman MT, Lo SK, Yadav D *et al.* A Randomized, Double-Blinded, Placebo-Controlled Trial of Simvastatin to Prevent Recurrent Pancreatitis. Pancreas 2022; 51:e10-e12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35195610>

38. Liang R, Ge W, Li B *et al.* Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs. Pharmaceutical biology 2022; 60:359-373. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35171063>
39. Hou YC, Shao YH. The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215243>
40. Kobayashi Y, Takeda T, Kunitomi H *et al.* Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. Pharmaceuticals (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215239>
41. Morofuji Y, Nakagawa S, Ujifuku K *et al.* Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals (Basel, Switzerland) 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215263>
42. Adamičková A, Gažová A, Adamička M *et al.* Molecular basis of the effect of atorvastatin pretreatment on stem cell therapy in chronic ischemic diseases - critical limb ischemia. Physiological research / Academia Scientiarum Bohemoslovaca 2021; 70:S527-s533. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199541>
43. Riesen WF. (Pleiotropic Effects of Statins - What Is Their Clinical Significance?). Praxis 2022; 110:86-88. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35105210>
44. Sheikhhassani V, Evers TMJ, Lamba S *et al.* Single cell force spectroscopy of erythrocytes at physiological and febrile temperatures reveals mechano-modulatory effects of atorvastatin. Soft Matter 2022; 18:2143-2148. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35201243>
45. Cai S, Chen Q, Xu Y *et al.* Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. Transl Cancer Res 2020; 9:1439-1447. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35117491>
46. Chen Y, Li F, Wu K *et al.* Do statins improve the survival time after esophagectomy? - a propensity score matching study. Transl Cancer Res 2020; 9:2295-2299. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35117590>
47. Li Z, Li Y, Li X *et al.* Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2022; 33:136-144. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35115293>
48. Uemura N, Hayashi H, Baba H. Statin as a therapeutic agent in gastroenterological cancer. World J Gastrointest Oncol 2022; 14:110-123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35116106>
49. Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14:119-139. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35126843>

Primary Prevention

1. Wagner JR, Fitzpatrick JK, Yang J *et al.* Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study. Am J Prev Cardiol 2022; 9:100319. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199077>
2. Kim S, Choi H, Won CW. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and

- older. Archives of gerontology and geriatrics 2022; 100:104644. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35121242>
3. Baharudin N, Mohamed-Yassin MS, Daher AM *et al.* Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study. BMC public health 2022; 22:228. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35120488>
 4. Tsimikas S. Lipoprotein(a) and Coronary Calcium: Clinical Management and Potential Design of Primary Prevention Trials. J Am Coll Cardiol 2022; 79:769-771. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35210031>
 5. Marcus ME, Manne-Goehler J, Theilmann M *et al.* Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. The Lancet. Global health 2022; 10:e369-e379. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180420>
 6. Raal FJ, Mohamed F. Statins: are they appropriate for all patients? The Lancet. Global health 2022; 10:e305-e306. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180403>

Registry data

1. Zhang Y, Zhao X, Ding X *et al.* Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L. Angiology 2022;33197221075861. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35191328>
2. Sung FC, Yeh YT, Muo CH *et al.* Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35159093>
3. Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovascular diabetology 2022; 21:28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35193571>
4. Rinella ME, Satapathy SK, Brandman D *et al.* Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35189388>
5. Huh JH, Park SW, Go TH *et al.* Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea. Frontiers in cardiovascular medicine 2021; 8:812416. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35127872>
6. Yao Y, Li X, Wang Z *et al.* Interaction of Lipids, Mean Platelet Volume, and the Severity of Coronary Artery Disease Among Chinese Adults: A Mediation Analysis. Frontiers in cardiovascular medicine 2022; 9:753171. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35174229>
7. Yi SW, An SJ, Park HB *et al.* Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. International journal of epidemiology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218344>
8. Wong C, Chu P, Teoh J *et al.* Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre

- cohort study. International urology and nephrology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35217907>
9. Mazard T, Ritzenthaler T, Dailier F. Pravastatin may improve neurological outcome following low-grade aneurysmal subarachnoid hemorrhage. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; 98:11-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35131719>
 10. Xu Y, Guo S, Jiang H *et al.* Collateral Status and Clinical Outcomes after Mechanical Thrombectomy in Patients with Anterior Circulation Occlusion. J Healthc Eng 2022; 2022:7796700. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35126946>
 11. Nelson AJ, O'Brien EC, Kaltenbach LA *et al.* Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA network open 2022; 5:e2148030. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175345>
 12. Zou X, Nie L, Liao Y *et al.* Effects of statin therapy and treatment duration on cardiovascular disease risk in patients with nephrotic syndrome: A nested case-control study. Pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184315>
 13. Ryu WS, Hong KS, Jeong SW *et al.* Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: A cohort study. PLoS Med 2022; 19:e1003910. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35120123>
 14. To YH, Tan XM, Low CL *et al.* Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score. Singapore medical journal 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35139626>
 15. Chen Y, Li F, Wu K *et al.* Do statins improve the survival time after esophagectomy? - a propensity score matching study. Transl Cancer Res 2020; 9:2295-2299. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35117590>
 16. Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14:119-139. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35126843>

Renal Disease

1. Sung FC, Yeh YT, Muo CH *et al.* Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35159093>
2. Rosenstein K, Tannock LR. Dyslipidemia in Chronic Kidney Disease. In: Endotext. Edited by: Feingold KR, Anawalt B, Boyce A *et al.* South Dartmouth (MA): MDText.com, Inc Copyright © 2000-2022, MDText.com, Inc.; 2000.
3. Wagner B, Escobar GP, Jackson DB, DeAguero J. Rosuvastatin-Induced Rhabdomyolysis, Pancreatitis, Transaminitis, and Acute Kidney Injury. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2021; 38:S18-s22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35136340>
4. Rønning M, Hjellvik V, Sakshaug S *et al.* Use of Statins in Kidney Transplant Recipients in Norway. International journal of environmental research and public health 2022; 19. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35162389>
5. Zou X, Nie L, Liao Y *et al.* Effects of statin therapy and treatment duration on cardiovascular disease risk in patients with nephrotic syndrome: A nested case-control study. Pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184315>

Reviews

1. Crupi R, Cuzzocrea S. Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance. *Biomolecules* 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35204743>
2. Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35158055>
3. Gohlke BO, Zincke F, Eckert A *et al.* Real-world evidence for preventive effects of statins on cancer incidence: A trans-Atlantic analysis. *Clinical and translational medicine* 2022; 12:e726. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184411>
4. Jar RA, Melibari E, Almeahadi N *et al.* A Cross-Sectional Study of the Current Management of Hypertriglyceridemia. *Cureus* 2021; 13:e20732. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35111425>
5. Santacruz JC, Mantilla MJ, Rueda I *et al.* Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist. *Cureus* 2022; 14:e21090. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165550>
6. Heiston EM, Hundley WG. Statins for Cardiac and Vascular Protection During and After Cancer Therapy. *Curr Oncol Rep* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199294>
7. Wei N, Hu Y, Liu G *et al.* A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021. *Curr Probl Cardiol* 2022:101151. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35202707>
8. Reijman MD, Schweizer A, Peterson ALH *et al.* Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. *Eur J Prev Cardiol* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175352>
9. Whitlon DS. Statins and hearing. *Hear Res* 2022:108453. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35125240>
10. Anagnostis P, Florentin M, Livadas S *et al.* Bone Health in Patients with Dyslipidemias: An Underestimated Aspect. *Int J Mol Sci* 2022; 23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35163560>
11. Subramanian S. Approach to the Patient with Moderate Hypertriglyceridemia. *J Clin Endocrinol Metab* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184196>
12. Morofuji Y, Nakagawa S, Ujifuku K *et al.* Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. *Pharmaceuticals (Basel, Switzerland)* 2022; 15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35215263>
13. Riesen WF. (Pleiotropic Effects of Statins - What Is Their Clinical Significance?). *Praxis* 2022; 110:86-88. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35105210>
14. Scheen AJ, Paquot N, Wallemacq C. (Bempedoic acid, new cholesterol-lowering drug). *Revue medicale de Liege* 2022; 77:124-131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35143133>
15. Uemura N, Hayashi H, Baba H. Statin as a therapeutic agent in gastroenterological cancer. *World J Gastrointest Oncol* 2022; 14:110-123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35116106>
16. Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? *World J Hepatol* 2022; 14:119-139. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35126843>

Safety and side effects

1. Rosenberg K. Statin Use Associated with Diabetes Progression. The American journal of nursing 2022; 122:45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200187>
2. Abed W, Abujbara M, Batieha A, Ajlouni K. Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. Annals of medicine and surgery (2012) 2022; 74:103304. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35145672>
3. Rodríguez-Expósito RL, Sifaoui I, Reyes-Batlle M *et al.* Statins Induce Actin Cytoskeleton Disassembly and an Apoptosis-Like Process in *Acanthamoeba* spp. Antibiotics (Basel, Switzerland) 2022; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35203882>
4. Ozen G, Dell'Aniello S, Pedro S *et al.* Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis. Arthritis care & research 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35119769>
5. Lavallee M, Yu T, Evans L *et al.* Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases. BMC medical informatics and decision making 2022; 22:31. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35115001>
6. Chang M, Bathena S, Christopher LJ *et al.* Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling. Cancer Chemother Pharmacol 2022; 89:383-392. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35147740>
7. Croyal M, Wargny M, Chemello K *et al.* Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovascular diabetology 2022; 21:21. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130909>
8. Joseph VMK, Rose EC, Edwards CJ *et al.* Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series. Clinical and experimental rheumatology 2022; 40:298-303. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35200125>
9. McCrea JB, Menzel K, Adedoyin A *et al.* Drug-Drug Interaction of Letemovir and Atorvastatin in Healthy Participants. Clinical pharmacology in drug development 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35157785>
10. Cooper-DeHoff RM, Niemi M, Ramsey LB *et al.* The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms. Clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35152405>
11. Storelli F, Li CY, Sachar M *et al.* Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug. Clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35152400>
12. Bytyçi I, Penson PE, Mikhailidis DP *et al.* Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35169843>
13. Imarhia FI, Sulaica EM, Varisco T, Pilate M. Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2021; 38:e67-e71. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35136343>
14. Wagner B, Escobar GP, Jackson DB, DeAgüero J. Rosuvastatin-Induced Rhabdomyolysis, Pancreatitis, Transaminitis, and Acute Kidney Injury. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2021; 38:S18-s22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35136340>

15. Grunwald SA, Haafke S, Grieben U *et al.* Statins Aggravate the Risk of Insulin Resistance in Human Muscle. Int J Mol Sci 2022; 23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35216514>
16. Chi CL, Wang J, Ying Yew P *et al.* Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning. J Biomed Inform 2022; 128:104029. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35182785>
17. Mazard T, Ritzenthaler T, Dailler F. Pravastatin may improve neurological outcome following low-grade aneurysmal subarachnoid hemorrhage. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; 98:11-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35131719>
18. Sverre E, Peersen K, Kristiansen O *et al.* Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects. Journal of internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35103360>
19. Ganatra RB, Bhatnagar A, Herzig SJ. Strengthening a Study of Diabetes Progression After Statin Use. JAMA Intern Med 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188529>
20. Mansi IA, Lingvay I, Alvarez CA. Strengthening a Study of Diabetes Progression After Statin Use-Reply. JAMA Intern Med 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188526>
21. Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175631>
22. Hanotte B, Gaultier JB, Abravanel F *et al.* (Rhabdomyolysis with tetraparesis secondary to hepatitis E virus infection in a patient on statins). La Revue de medecine interne / fondee ... par la Societe nationale francaise de medecine interne 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35131129>
23. Tran T, Mach J, Gemikonakli G *et al.* Diurnal effects of polypharmacy with high drug burden index on physical activities over 23 h differ with age and sex. Scientific reports 2022; 12:2168. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35140291>

Stroke and CNS

1. Wang D, Tian Y, Wei H *et al.* Risk Factor Analysis of the Conservative Treatment in Chronic Subdural Hematomas: A Substudy of the ATOCH Trial. Adv Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35133631>
2. Cui C, Li Q, Li C *et al.* Statin pretreatment combined with intravenous thrombolysis for ischemic stroke patients: A meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; 98:142-148. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35180504>
3. Mazard T, Ritzenthaler T, Dailler F. Pravastatin may improve neurological outcome following low-grade aneurysmal subarachnoid hemorrhage. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; 98:11-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35131719>
4. Xu Y, Guo S, Jiang H *et al.* Collateral Status and Clinical Outcomes after Mechanical Thrombectomy in Patients with Anterior Circulation Occlusion. J Healthc Eng 2022; 2022:7796700. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35126946>
5. Santos AN, Rauschenbach L, Saban D *et al.* Medication intake and hemorrhage risk in patients with familial cerebral cavernous malformations. Journal of neurosurgery. 2022:1-7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35213840>

6. Al-Rubiay HF, Al-Kuraishy HM, Al-Gareeb AI. Intercellular adhesive molecule 1(ICAM-1) and acute ischaemic stroke: Role of statins. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S11-s16. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130210>
7. Naji MT, Al-Kuraishy HM, Al-Gareeb AI. Differential effects of statins on matrix metalloproteinase-9 (MMP-9) in patients with acute ischaemic stroke: A potential for salutary. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S82-s87. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130225>
8. Lee M, Cheng CY, Wu YL *et al.* Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA neurology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188949>
9. Stefanou MI, Palaiodimou L, Katsanos AH *et al.* The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis. Multiple sclerosis and related disorders 2022; 58:103395. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35216778>
10. Jeong W, Joo JH, Kim H *et al.* Association between statin adherence and the risk of stroke among South Korean adults with hyperlipidemia. Nutrition, metabolism, and cardiovascular diseases : NMCD 2022; 32:560-566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35105503>
11. Ryu WS, Hong KS, Jeong SW *et al.* Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: A cohort study. PLoS Med 2022; 19:e1003910. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35120123>
12. Park SY, Rhi SH, Chung JY *et al.* Rapid Regression of Carotid Artery Stenosis Shortly after Intensive Medical Therapy. Tomography 2022; 8:543-549. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35202209>

Triglycerides/HDL

1. Wagner JR, Fitzpatrick JK, Yang J *et al.* Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study. Am J Prev Cardiol 2022; 9:100319. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199077>
2. Asztalos BF, Hauser TH, Goldfine AB *et al.* The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity. Atherosclerosis 2022; 345:1-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35183903>
3. Siudut J, Natarska J, Wypasek E *et al.* Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis. Atherosclerosis 2022; 344:49-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35134656>
4. Zhang Q, He J, Xu F *et al.* Correction: Supramolecular copolymer modified statin-loaded discoidal rHDLs for atherosclerotic anti-inflammatory therapy by cholesterol efflux and M2 macrophage polarization. Biomaterials science 2022; 10:1594-1595. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35195139>
5. Jar RA, Melibari E, Almeahmadi N *et al.* A Cross-Sectional Study of the Current Management of Hypertriglyceridemia. Cureus 2021; 13:e20732. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35111425>
6. Subramanian S. Approach to the Patient with Moderate Hypertriglyceridemia. J Clin Endocrinol Metab 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35184196>
7. Weintraub WS, Bhatt DL, Zhang Z *et al.* Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA network open 2022; 5:e2148172. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35157055>

Trials

1. Wang D, Tian Y, Wei H *et al.* Risk Factor Analysis of the Conservative Treatment in Chronic Subdural Hematomas: A Substudy of the ATOCH Trial. Adv Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35133631>
2. Lindell OP, Karlsson LO, Nilsson S *et al.* Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care. Am Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35181275>
3. Verma KP, Marwick T, Duarte C *et al.* Use of Coronary Computed Tomography or Polygenic Risk Scores to Prompt Action to Reduce Coronary Artery Disease Risk: The CAPAR-CAD Trial. Am Heart J 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35218726>
4. Wagner JR, Fitzpatrick JK, Yang J *et al.* Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study. Am J Prev Cardiol 2022; 9:100319. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35199077>
5. Murata Y, Isayama R, Imai S *et al.* A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial. Contemporary clinical trials communications 2022; 26:100892. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35198792>
6. Rupasinghe CD, Kantas T, Sani R *et al.* Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial. Cureus 2021; 13:e20710. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35106245>
7. Ray KK, Dhalwani N, Sibartie M *et al.* Low density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. European heart journal. Quality of care & clinical outcomes 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35175350>
8. Yerino GA, Feleder EC, Halabe EK *et al.* Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide and rosuvastatin in healthy adult subjects. International journal of clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35103587>
9. Al-Rubiy HF, Al-Kuraishy HM, Al-Gareeb AI. Intercellular adhesive molecule 1(ICAM-1) and acute ischaemic stroke: Role of statins. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S11-s16. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130210>
10. Naji MT, Al-Kuraishy HM, Al-Gareeb AI. Differential effects of statins on matrix metalloproteinase-9 (MMP-9) in patients with acute ischaemic stroke: A potential for salutary. JPMA. The Journal of the Pakistan Medical Association 2021; 71(Suppl 8):S82-s87. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35130225>
11. Ganatra RB, Bhatnagar A, Herzig SJ. Strengthening a Study of Diabetes Progression After Statin Use. JAMA Intern Med 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188529>
12. Mansi IA, Lingvay I, Alvarez CA. Strengthening a Study of Diabetes Progression After Statin Use-Reply. JAMA Intern Med 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35188526>
13. Goodman MT, Lo SK, Yadav D *et al.* A Randomized, Double-Blinded, Placebo-Controlled Trial of Simvastatin to Prevent Recurrent Pancreatitis. Pancreas 2022; 51:e10-e12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35195610>

Women and elderly

1. Fang J, Zhang X. Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris. American journal of translational research 2022; 14:594-602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35173877>
2. Kim S, Choi H, Won CW. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and older. Archives of gerontology and geriatrics 2022; 100:104644. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35121242>
3. Mauricio R, Khera A. Statin Use in Pregnancy: Is It Time For a Paradigm Shift? Circulation 2022; 145:496-498. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35157518>
4. Santacruz JC, Mantilla MJ, Rueda I *et al.* Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist. Cureus 2022; 14:e21090. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35165550>
5. Visser AGR, Schols J, Prevoo M *et al.* Deprescribing Statins and Proton Pump Inhibitors in Nursing Home Residents; a Pragmatic Exploratory Study. Gerontol Geriatr Med 2021; 7:23337214211050807. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35187202>
6. El Sabeh M, Vincent KL, Afrin S *et al.* Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study. J Obstet Gynaecol 2022:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35166183>
7. Chen YY, Li TC, Li CI *et al.* Statins Associated with Better Long-Term Outcomes in Aged Hospitalized Patients with COPD: A Real-World Experience from Pay-for-Performance Program. Journal of personalized medicine 2022; 12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35207787>



You are now on the mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.

This activity is supported by an educational grant from Viatrix.
© P.J. Lansberg